BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20471443)

  • 1. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
    Zhang R; Zhang S; Li M; Chen C; Yao Q
    Vaccine; 2010 Jul; 28(31):5114-27. PubMed ID: 20471443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.
    Yao Q; Zhang R; Guo L; Li M; Chen C
    J Immunol; 2004 Aug; 173(3):1951-8. PubMed ID: 15265929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles.
    Guo L; Lu X; Kang SM; Chen C; Compans RW; Yao Q
    Virology; 2003 Sep; 313(2):502-13. PubMed ID: 12954217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.
    Franco D; Liu W; Gardiner DF; Hahn BH; Ho DD
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):393-400. PubMed ID: 21239998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles.
    Yao Q
    Res Initiat Treat Action; 2003; 8(2):20-1. PubMed ID: 12845773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
    Silva de Castro I; Gordon SN; Liu J; Bissa M; McKinnon K; Trinh HV; Doster MN; Schifanella L; Liyanage NP; Cao J; Cheng O; Foulds K; Roederer M; Koup RA; Shen X; Tomaras GD; Venzon DJ; Forthal DN; Fouts T; Montefiori DC; Tartaglia J; Rao M; Ostrowski M; Franchini G; Vaccari M
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31896599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses.
    Ao Z; Wang L; Mendoza EJ; Cheng K; Zhu W; Cohen EA; Fowke K; Qiu X; Kobinger G; Yao X
    PLoS One; 2019; 14(5):e0216949. PubMed ID: 31100082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHIV virus-like particles bind and activate human dendritic cells.
    Zhang R; Li M; Chen C; Yao Q
    Vaccine; 2004 Nov; 23(2):139-47. PubMed ID: 15531030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
    Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
    Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.
    Skountzou I; Quan FS; Gangadhara S; Ye L; Vzorov A; Selvaraj P; Jacob J; Compans RW; Kang SM
    J Virol; 2007 Feb; 81(3):1083-94. PubMed ID: 17108046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual Immunization with Chimeric C1q/CD40 Ligand/HIV Virus-like Particles Induces Strong Mucosal Immune Responses against HIV.
    Liu D; Zhang S; Poteet E; Marin-Muller C; Chen C; Yao Q
    Vaccines (Basel); 2021 Oct; 9(11):. PubMed ID: 34835167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
    Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
    J Virol; 2017 May; 91(9):. PubMed ID: 28202751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.